Adjuvant Docetaxel for Node-Positive Breast Cancer

2005951 citationsJournal Articlebronze Open Access

Authors

Miguel Martín · Hospital Clínico San Carlos

Tadeusz Pieńkowski · The Maria Sklodowska-Curie National Research Institute of Oncology

John R. Mackey

Marek Pawlicki · The Maria Sklodowska-Curie National Research Institute of Oncology

Jean‐Paul Guastalla · Centre Léon Bérard

Charles H. Weaver

Eva Tomiak · Regional Cancer Center

Taher Al‐Tweigeri

Abstract

Adjuvant chemotherapy with TAC, as compared with FAC, significantly improves the rates of disease-free and overall survival among women with operable node-positive breast cancer.

Topics & Keywords

Breast Cancer Treatment Studies Cancer Treatment and Pharmacology Breast Lesions and Carcinomas

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 352, Issue 22, pp. 2302-2313

DOI: 10.1056/nejmoa043681

Field-Weighted Citation Impact: 40.01